| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Apr―29 |
Characterization of binding affinity changes of SARS-CoV-2 omicron variant peptides to population-specific HLA |
Che-Mai Chang, Chang-Jiun Wu, Maxim Shkurnikov, Chin-Lin Guo, Wan-Chen Huang, Alexander Tonevitsky, Wei-Chiao Chang |
| 2 |
[GO] |
2024―Jul―13 |
A glimpse into viral warfare: decoding the intriguing role of highly pathogenic coronavirus proteins in apoptosis regulation |
Leyi Cheng, Yajuan Rui, Yanpu Wang, Shiqi Chen, Jiaming Su, Xiao-Fang Yu |
| 3 |
[GO] |
2024―Apr―18 |
Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19 |
Kun-Han Hsieh, Chiao-Hsuan Chao, Yi-Ling Cheng, Yen-Chung Lai, Yung-Chun Chuang, Jen-Ren Wang, Sui-Yuan Chang, Yuan-Pin Hung, Yi-Ming Arthur Chen, Wei-Lun Liu, Woei-Jer Chuang, Trai-Ming Yeh |
| 4 |
[GO] |
2023―Okt―12 |
Human ACE2 protein is a molecular switch controlling the mode of SARS-CoV-2 transmission |
Chao-Fu Yang, Chun-Che Liao, Hung-Wei Hsu, Jian-Jong Liang, Chih-Shin Chang, Hui-Ying Ko, Rue-Hsin Chang, Wei-Chun Tang, Ming-Hao Chang, I-Hsuan Wang, Yi-Ling Lin |
| 5 |
[GO] |
2023―Aug―22 |
ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification |
Chia-Wen Wang, Huai-Chia Chuang, Tse-Hua Tan |
| 6 |
[GO] |
2023―Jul―31 |
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2 |
Hsiao-Ling Chiang, Kang-Hao Liang, Ruei-Min Lu, Ting-Wen Kuo, Yi-Ling Lin, Han-Chung Wu |
| 7 |
[GO] |
2023―Jun―28 |
Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern |
Monika Kumari, Shih-Chieh Su, Kang-Hao Liang, Hsiu-Ting Lin, Yu-Feng Lu, Kai-Chi Chen, Wan-Yu Chen, Han-Chung Wu |
| 8 |
[GO] |
2023―Mai―03 |
Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19 |
Jaung-Geng Lin, Guan-Jhong Huang, Yi-Chang Su |
| 9 |
[GO] |
2022―Dez―22 |
Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants |
Shih-Han Ko, Wan-Yu Chen, Shih-Chieh Su, Hsiu-Ting Lin, Feng-Yi Ke, Kang-Hao Liang, Fu-Fei Hsu, Monika Kumari, Chi-Yu Fu, Han-Chung Wu |
| 10 |
[GO] |
2022―Nov―10 |
Dynamic modulations of urinary sphingolipid and glycerophospholipid levels in COVID-19 and correlations with COVID-19-associated kidney injuries |
Makoto Kurano, Daisuke Jubishi, Koh Okamoto, Hideki Hashimoto, Eri Sakai, Yoshifumi Morita, Daisuke Saigusa, Kuniyuki Kano, Junken Aoki, Sohei Harada, Shu Okugawa, Kent Doi, Kyoji Moriya, Yutaka Yatomi |
| 11 |
[GO] |
2022―Okt―26 |
The pathogenesis of coronavirus-19 disease |
Alain C. Borczuk, Rhonda K. Yantiss |
| 12 |
[GO] |
2022―Okt―15 |
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection |
Wei-Yu Chi, Yen-Der Li, Hsin-Che Huang, Timothy En Haw Chan, Sih-Yao Chow, Jun-Han Su, Louise Ferrall, Chien-Fu Hung, T.-C. Wu |
| 13 |
[GO] |
2022―Sep―12 |
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies |
Monika Kumari, Ruei-Min Lu, Mu-Chun Li, Jhih-Liang Huang, Fu-Fei Hsu, Shih-Han Ko, Feng-Yi Ke, Shih-Chieh Su, Kang-Hao Liang, Joyce Pei-Yi Yuan, Hsiao-Ling Chiang, Cheng-Pu Sun, I.-Jung Lee, Wen-Shan Li, Hsing-Pang Hsieh, Mi-Hua Tao, Han-Chung Wu |
| 14 |
[GO] |
2022―Jul―12 |
CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation |
Pei-Shan Sung, Shao-Ping Yang, Yu-Chun Peng, Cheng-Pu Sun, Mi-Hwa Tao, Shie-Liang Hsieh |
| 15 |
[GO] |
2022―Jul―07 |
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants |
I-Jung Lee, Cheng-Pu Sun, Ping-Yi Wu, Yu-Hua Lan, I-Hsuan Wang, Wen-Chun Liu, Joyce Pei-Yi Yuan, Yu-Wei Chang, Sheng-Che Tseng, Szu-I Tsung, Yu-Chi Chou, Monika Kumari, Yin-Shiou Lin, Hui-Feng Chen, Tsung-Yen Chen, Chih-Chao Lin, Chi-Wen Chiu, Chung-Hsuan Hsieh, Cheng-Ying Chuang, Chao-Min Cheng, Hsiu-Ting Lin, Wan-Yu Chen, Fu-Fei Hsu, Ming-Hsiang Hong, Chun-Che Liao, Chih-Shin Chang, Jian-Jong Liang, Hsiu-Hua Ma, Ming-Tsai Chiang, Hsin-Ni Liao, Hui-Ying Ko, Liang-Yu Chen, Yi-An Ko, Pei-Yu Yu, Tzu-Jing Yang, Po-Cheng Chiang, Shang-Te Hsu, Yi-Ling Lin, Chong-Chou Lee, Han-Chung Wu, Mi-Hua Tao |
| 16 |
[GO] |
2022―Jul―03 |
Dengue and COVID-19: two sides of the same coin |
Gathsaurie Neelika Malavige, Chandima Jeewandara, Graham S. Ogg |
| 17 |
[GO] |
2022―Jun―09 |
Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy |
Chen-Yi Chiang, Mei-Yu Chen, Chia-Wei Hsu, Chia-Yeh Liu, Yu-Wen Tsai, Hung-Chun Liao, Jia-Ying Yan, Zih-Shiuan Chuang, Hsin-I. Wang, Chien-Hsiung Pan, Chia-Yi Yu, Guann-Yi Yu, Ching-Len Liao, Shih-Jen Liu, Hsin-Wei Chen |
| 18 |
[GO] |
2022―Mai―03 |
The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy |
Yiran Wang, Mandi Wu, Yichen Li, Ho Him Yuen, Ming-Liang He |
| 19 |
[GO] |
2022―Jan―04 |
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection |
Yu-Chyi Hwang, Ruei-Min Lu, Shih-Chieh Su, Pao-Yin Chiang, Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, Tzung-Yang Hsieh, Han-Chung Wu |
| 20 |
[GO] |
2021―Nov―23 |
Antibody cocktail effective against variants of SARS-CoV-2 |
Kang-Hao Liang, Pao-Yin Chiang, Shih-Han Ko, Yu-Chi Chou, Ruei-Min Lu, Hsiu-Ting Lin, Wan-Yu Chen, Yi-Ling Lin, Mi-Hua Tao, Jia-Tsrong Jan, Han-Chung Wu |
| 21 |
[GO] |
2021―Jun―07 |
Identification of COVID-19 B-cell epitopes with phage-displayed peptide library |
Jing-You Guo, I-Ju Liu, Hsiu-Ting Lin, Mei-Jung Wang, Yu-Ling Chang, Shin-Chang Lin, Mei-Ying Liao, Wei-Chia Hsu, Yi-Ling Lin, James C. Liao, Han-Chung Wu |
| 22 |
[GO] |
2021―Apr―30 |
A novel pseudovirus-based mouse model of SARS-CoV-2 infection to test COVID-19 interventions |
Ssu-Hsueh Tseng, Brandon Lam, Yu Jui Kung, John Lin, Li Liu, Ya Chea Tsai, Louise Ferrall, Richard B. S. Roden, T. C. Wu, Chien-Fu Hung |
| 23 |
[GO] |
2021―Jan―12 |
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications |
Ioannis P. Trougakos, Kimon Stamatelopoulos, Evangelos Terpos, Ourania E. Tsitsilonis, Evmorfia Aivalioti, Dimitrios Paraskevis, Efstathios Kastritis, George N. Pavlakis, Meletios A. Dimopoulos |
| 24 |
[GO] |
2020―Dez―20 |
Coronavirus vaccine development: from SARS and MERS to COVID-19 |
Yen-Der Li, Wei-Yu Chi, Jun-Han Su, Louise Ferrall, Chien-Fu Hung, T.-C. Wu |
| 25 |
[GO] |
2020―Jun―07 |
The origin and underlying driving forces of the SARS-CoV-2 outbreak |
Shu-Miaw Chaw, Jui-Hung Tai, Shi-Lun Chen, Chia-Hung Hsieh, Sui-Yuan Chang, Shiou-Hwei Yeh, Wei-Shiung Yang, Pei-Jer Chen, Hurng-Yi Wang |
| 26 |
[GO] |
2020―Jun―04 |
Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) |
Feng-Yee Chang, Hsiang-Cheng Chen, Pei-Jer Chen, Mei-Shang Ho, Shie-Liang Hsieh, Jung-Chung Lin, Fu-Tong Liu, Huey-Kang Sytwu |
|
